

# Eva Kubala Havrdova

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6961707/eva-kubala-havrdova-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

282 papers	23,818 citations	64 h-index	151 g-index
319 ext. papers	27,733 ext. citations	7.3 avg, IF	6.23 L-index

#	Paper	IF	Citations
282	Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 57, 103389	4	1
281	Steroid Sulfation in Neurodegenerative Diseases.. <i>Frontiers in Molecular Biosciences</i> , <b>2022</b> , 9, 839887	5.6	1
280	Multiple Sclerosis Relapses Following Cessation of Fingolimod.. <i>Clinical Drug Investigation</i> , <b>2022</b> , 42, 3553.2	3.2	1
279	Time course of lesion-induced atrophy in multiple sclerosis.. <i>Journal of Neurology</i> , <b>2022</b> , 1	5.5	0
278	Periventricular gradient of T tissue alterations in multiple sclerosis.. <i>NeuroImage: Clinical</i> , <b>2022</b> , 34, 103099	9.9	1
277	Flow Cytometry Analysis of Blood Large Extracellular Vesicles in Patients with Multiple Sclerosis Experiencing Relapse of the Disease. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11, 2832	5.1	0
276	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , <b>2021</b> , 96, e783-e797	6.5	18
275	Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 2001-2013	5	2
274	Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. <i>Journal of Neurology</i> , <b>2021</b> , 1	5.5	4
273	Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a. <i>Neurology</i> , <b>2021</b> , 96, e214-e227	6.5	2
272	Isolated Cognitive Decline in Neurologically Stable Patients with Multiple Sclerosis. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	1
271	Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2021</b> , 8,	9.1	3
270	Effects of Menopause in Women With Multiple Sclerosis: An Evidence-Based Review. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 554375	4.1	4
269	Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , <b>2021</b> ,	6.5	8
268	Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. <i>JAMA Neurology</i> , <b>2021</b> , 78, 558-567	17.2	39
267	Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. <i>European Journal of Neurology</i> , <b>2021</b> ,	6	6
266	The potential of serum neurofilament as biomarker for multiple sclerosis. <i>Brain</i> , <b>2021</b> , 144, 2954-2963	11.2	19

265	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 51, 102844	4	3
264	Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , <b>2021</b> , 97, e869-e880	6.5	3
263	Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 220-231	5	24
262	The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 479-482	5	2
261	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 755-766	5	3
260	Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 52-60	5	11
259	Interpretation of Brain Volume Increase in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , <b>2021</b> , 31, 401-407	2.8	4
258	Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2021</b> , 14, 1756286420982134	6.6	11
257	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 1838-1851	5	2
256	The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 53, 103012	4	3
255	Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. <i>Journal of Neuroimmunology</i> , <b>2021</b> , 357, 577627	3.5	8
254	The clinical and paraclinical correlates of employment status in multiple sclerosis. <i>Neurological Sciences</i> , <b>2021</b> , 1	3.5	1
253	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. <i>Computer Methods and Programs in Biomedicine</i> , <b>2021</b> , 208, 106180	6.9	2
252	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , <b>2021</b> , 35, 1217-1232	6.7	1
251	Severely disabled multiple sclerosis patients can achieve the performance of healthy subjects after expiratory muscle strength training. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 55, 103187	4	
250	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.. <i>Pharmacoeconomics</i> , <b>2021</b> , 40, 323	4.4	
249	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211061335	5.2	11
248	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , <b>2020</b> , 143, 1400-1413	11.2	13

247	Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. <i>Neurology and Therapy</i> , <b>2020</b> , 9, 443-457	4.6	4
246	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 1352458520924595	5	6
245	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 1352458520925369	5	14
244	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology</i> , <b>2020</b> , 19, 307-316	24.1	77
243	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003348	11.6	13
242	Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. <i>Journal of Neurology</i> , <b>2020</b> , 267, 2851-2864	5.5	4
241	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 38, 101868	4	15
240	Quantitative proteomic analysis of cerebrospinal fluid of women newly diagnosed with multiple sclerosis. <i>International Journal of Neuroscience</i> , <b>2020</b> , 1-11	2	3
239	The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 46, 102534	4	5
238	Association of Pregnancy With the Onset of Clinically Isolated Syndrome. <i>JAMA Neurology</i> , <b>2020</b> , 77, 1496-1503	17.2	11
237	Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. <i>Journal of Clinical Lipidology</i> , <b>2020</b> , 14, 675-684.e2	4.9	4
236	Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFN- $\beta$ . <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 1527	8.4	13
235	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. <i>JAMA Neurology</i> , <b>2020</b> , 77, 1398-1407	17.2	8
234	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , <b>2020</b> , 143, 2742-2756	11.2	8
233	Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2020</b> , 13, 1756286420975223	6.6	2
232	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 79-90	5	27
231	Monitoring of radiologic disease activity by serum neurofilaments in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2020</b> , 7,	9.1	16
230	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <i>Lancet Neurology</i> , <b>2019</b> , 18, 1009-1020	24.1	96

229	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <i>Lancet Neurology, The</i> , <b>2019</b> , 18, 1021-1033	24.1	98
228	Slowed articulation rate is associated with information processing speed decline in multiple sclerosis: A pilot study. <i>Journal of Clinical Neuroscience</i> , <b>2019</b> , 65, 28-33	2.2	9
227	Why patients with multiple sclerosis perceive improvement of gait during treatment with natalizumab?. <i>Journal of Neural Transmission</i> , <b>2019</b> , 126, 731-737	4.3	3
226	Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 1273-1288	5	23
225	A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS. <i>American Journal of Neuroradiology</i> , <b>2019</b> , 40, 446-452	4.4	12
224	Real-Life Outcome in Multiple Sclerosis in the Czech Republic. <i>Multiple Sclerosis International</i> , <b>2019</b> , 2019, 7290285	1.1	4
223	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 1255-1262	5	24
222	Additive Effect of Spinal Cord Volume, Diffuse and Focal Cord Pathology on Disability in Multiple Sclerosis. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 820	4.1	7
221	Biofeedback Based Home Balance Training can Improve Balance but Not Gait in People with Multiple Sclerosis. <i>Multiple Sclerosis International</i> , <b>2019</b> , 2019, 2854130	1.1	4
220	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. <i>Journal of Neuroimmunology</i> , <b>2019</b> , 326, 19-27	3.5	9
219	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, 458-468	5.5	46
218	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 28, 235-243	4	22
217	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 321, 175-187	27.4	172
216	Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. <i>European Journal of Neurology</i> , <b>2019</b> , 26, 363-370	6	8
215	Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 1605-1617	5	46
214	Pathological cut-offs of global and regional brain volume loss in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 541-553	5	22
213	Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , <b>2018</b> , 388, 87-93	3.2	5
212	Establishing pathological cut-offs for lateral ventricular volume expansion rates. <i>NeuroImage: Clinical</i> , <b>2018</b> , 18, 494-501	5.3	15

211	Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 22, 166	4	
210	Management of multiple sclerosis patients in central European countries: current needs and potential solutions. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2018</b> , 11, 1756286418759189	6.6	12
209	Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 19, 105-108	4	15
208	The Role of High-Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , <b>2018</b> , 28, 328-337	2.8	4
207	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. <i>Brain</i> , <b>2018</b> , 141, 1085-1093	11.2	72
206	Cognitive clinico-radiological paradox in early stages of multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , <b>2018</b> , 5, 81-91	5.3	17
205	ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. <i>European Journal of Neurology</i> , <b>2018</b> , 25, 215-237	6	96
204	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 96-120	5	286
203	Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management. <i>European Journal of Neurology</i> , <b>2018</b> , 25, 739-746	6	7
202	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2018</b> , 4, 2055217318760642	2	19
201	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology</i> , <b>2018</b> , 17, 405-415	24.1	150
200	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 642-652	5	18
199	Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 1883-1891	5	2
198	Cladribine versus fingolimod, natalizumab and interferon $\beta$ for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 1617-1626	5	21
197	Monocyte NOTCH2 expression predicts IFN- $\gamma$ immunogenicity in multiple sclerosis patients. <i>JCI Insight</i> , <b>2018</b> , 3,	9.9	11
196	Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 19, 153-160	4	66
195	Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study. <i>NeuroImage: Clinical</i> , <b>2018</b> , 17, 444-451	5.3	41
194	060 Association of brain volume loss and neda outcomes in patients with relapsing multiple sclerosis in the opera i and opera ii studies (ENCORE). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2018</b> , 89, A25.1-A25	5.5	



193	Do eyes with and without optic neuritis in multiple sclerosis age equally?. <i>Neuropsychiatric Disease and Treatment</i> , <b>2018</b> , 14, 2281-2285	3.1	3
192	Gender Inequities in the Multiple Sclerosis Community: A Call for Action. <i>Annals of Neurology</i> , <b>2018</b> , 84, 958-959	9.4	5
191	044 Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2018</b> , 89, A18.2-A19	5.5	
190	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 24, 11-19	4	12
189	Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 242-252	5	30
188	The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 94-105	5	56
187	Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 51-61	5	31
186	Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 253-265	5	105
185	Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 266-276	5	22
184	Survey of diagnostic and treatment practices for multiple sclerosis in Europe. <i>European Journal of Neurology</i> , <b>2017</b> , 24, 516-522	6	27
183	Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. <i>JAMA Neurology</i> , <b>2017</b> , 74, 459-469	17.2	147
182	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, 196-203	5.5	43
181	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology, The</i> , <b>2017</b> , 16, 271-281	24.1	101
180	Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 658-665	13.6	76
179	A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study. <i>Journal of Neuroimaging</i> , <b>2017</b> , 27, 620-629	2.8	16
178	Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. <i>European Journal of Neurology</i> , <b>2017</b> , 24, 726-733	6	38
177	No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1736-1747	5	15
176	"No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1179-1187	5	90

175	MxA mRNA decrease preceding NAb detection in IFNβ-treated MS patients. <i>Brain and Behavior</i> , <b>2017</b> , 7, e00644	3.4	1
174	Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2017</b> , 11, 18-24	4	9
173	Serum lipid profile changes predict neurodegeneration in interferon-βa-treated multiple sclerosis patients. <i>Journal of Lipid Research</i> , <b>2017</b> , 58, 403-411	6.3	23
172	Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients. <i>BMC Neurology</i> , <b>2017</b> , 17, 145	3.1	5
171	Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program. <i>Therapeutics and Clinical Risk Management</i> , <b>2017</b> , 13, 1423-1437	2.9	17
170	Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. <i>Neurology</i> , <b>2017</b> , 89, 1107-1116	6.5	139
169	Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. <i>Neurology</i> , <b>2017</b> , 89, 1117-1126	6.5	175
168	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. <i>Neurology</i> , <b>2017</b> , 89, 1050-1059	6.5	31
167	Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, e1.11-e1	5.5	
166	New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 41-52	5	12
165	Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. <i>NeuroImage: Clinical</i> , <b>2017</b> , 15, 769-779	5.3	27
164	Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2017</b> , 17, 32-40	4	7
163	Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1367-1376	5.7	21
162	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1346-1357	5	13
161	Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach. <i>European Journal of Neurology</i> , <b>2017</b> , 24, 292-301	6	20
160	PO114 Neda achievement by time interval with daclizumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, A42.1-A42	5.5	
159	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , <b>2017</b> , 140, 2426-2443	11.2	62
158	PO129 Neda analysis by epoch in the OPERA studies of ocrelizumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, A46.2-A46	5.5	1



157	Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFN- $\beta$ <i>PLoS ONE</i> , <b>2017</b> , 12, e0169957	3.7	
156	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 520-32	5	30
155	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 126-9	5.5	66
154	Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon $\beta$ 1a in MS. <i>Neurology</i> , <b>2016</b> , 87, 1464-1472	6.5	21
153	Reliable measurements of brain atrophy in individual patients with multiple sclerosis. <i>Brain and Behavior</i> , <b>2016</b> , 6, e00518	3.4	45
152	Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program. <i>Neurology and Therapy</i> , <b>2016</b> , 5, 169-182	4.6	13
151	Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. <i>BMC Neurology</i> , <b>2016</b> , 16, 117	3.1	34
150	Quantification of Gait Abnormalities in Healthy-Looking Multiple Sclerosis Patients (with Expanded Disability Status Scale 0-1.5). <i>European Neurology</i> , <b>2016</b> , 76, 99-104	2.1	11
149	ALEMTUZUMAB PERSISTENTLY SLOWS BRAIN VOLUME LOSS IN RRMS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, e1.30-e1	5.5	
148	DACLIZUMAB HYP IN MULTIPLE SCLEROSIS: 3-YEAR RESULTS FROM SELECTED. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, e1.48-e1	5.5	
147	DACLIZUMAB HYP VS IM INTERFERON BETA-1A IN MS: NEDA RESULTS FROM DECIDE. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, e1.47-e1	5.5	1
146	Predictors of long-term disability accrual in relapse-onset multiple sclerosis. <i>Annals of Neurology</i> , <b>2016</b> , 80, 89-100	9.4	117
145	MENACTRIMS congress 2016. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, NP1-NP24	5	2
144	Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. <i>Lancet Neurology, The</i> , <b>2016</b> , 15, 574-84	24.1	194
143	A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1709-1718	5	54
142	Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 770-81	5	26
141	Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. <i>European Journal of Neurology</i> , <b>2016</b> , 23, 412-5	6	7
140	Defining secondary progressive multiple sclerosis. <i>Brain</i> , <b>2016</b> , 139, 2395-405	11.2	172

139	Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. <i>European Journal of Neurology</i> , <b>2016</b> , 23, 729-36	6	19
138	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 1343-1349	5.5	44
137	Comparative efficacy of first-line natalizumab vs IFN- $\beta$ glatiramer acetate in relapsing MS. <i>Neurology: Clinical Practice</i> , <b>2016</b> , 6, 102-115	1.7	21
136	Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. <i>Multiple Sclerosis and Related Disorders</i> , <b>2016</b> , 6, 66-72	4	13
135	Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. <i>Journal of Neurology</i> , <b>2016</b> , 263, 1287-95	5.5	109
134	Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. <i>Neurology</i> , <b>2016</b> , 87, 1985-1992	6.5	38
133	Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group. <i>Multiple Sclerosis and Related Disorders</i> , <b>2015</b> , 4, 202-18	4	62
132	Spatial and temporal characteristics of gait as outcome measures in multiple sclerosis (EDSS 0 to 6.5). <i>Journal of NeuroEngineering and Rehabilitation</i> , <b>2015</b> , 12, 14	5.3	43
131	Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon $\beta$ 1a. <i>European Journal of Neurology</i> , <b>2015</b> , 22, 1113-23	6	22
130	BREMSO: a simple score to predict early the natural course of multiple sclerosis. <i>European Journal of Neurology</i> , <b>2015</b> , 22, 981-9	6	23
129	Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. <i>JAMA Neurology</i> , <b>2015</b> , 72, 405-13	17.2	83
128	Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients. <i>Journal of Lipid Research</i> , <b>2015</b> , 56, 2010-8	6.3	33
127	Impaired ambulation and steroid therapy impact negatively on bone health in multiple sclerosis. <i>European Journal of Neurology</i> , <b>2015</b> , 22, 624-32	6	11
126	Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1418-28	59.2	203
125	Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome. <i>American Journal of Neuroradiology</i> , <b>2015</b> , 36, 1457-64	4.4	9
124	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , <b>2015</b> , 138, 3287-98	11.2	107
123	Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. <i>Clinical Therapeutics</i> , <b>2015</b> , 37, 2543-51	3.5	5
122	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 1159-71	5	30

121	Hidden Factors influencing quality of life in patients with multiple sclerosis. <i>European Journal of Neurology</i> , <b>2015</b> , 22 Suppl 2, 28-33	6	32
120	ALEMTUZUMAB IMPROVES 3-YEAR QUALITY OF LIFE IN CARE-MS II. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2015</b> , 86, e4.9-e4	5.5	
119	Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. <i>Clinical and Experimental Immunology</i> , <b>2015</b> , 181, 385-400	6.2	62
118	Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience. <i>Neurology and Therapy</i> , <b>2015</b> , 4, 93-104	4.6	62
117	MANAGEMENT OF ADVERSE REACTIONS TO ALEMTUZUMAB INFUSION. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2015</b> , 86, e4.23-e4	5.5	1
116	Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , <b>2015</b> , 77, 425-35	9.4	118
115	Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM. <i>European Journal of Neurology</i> , <b>2015</b> , 22, 570-7	6	11
114	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 1013-24	5	181
113	Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. <i>Neurology</i> , <b>2015</b> , 84, 1145-52	6.5	47
112	Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2015</b> , 8, 31-45	6.6	96
111	Increased serum levels of C21 steroids in female patients with multiple sclerosis. <i>Physiological Research</i> , <b>2015</b> , 64, S247-54	2.1	7
110	Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate. <i>International Journal of MS Care</i> , <b>2015</b> , 17, 236-43	2.3	40
109	The comparison of selected cerebrospinal fluid and serum cytokine levels in patients with multiple sclerosis and normal pressure hydrocephalus. <i>Neuroendocrinology Letters</i> , <b>2015</b> , 36, 564-71	0.3	13
108	A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. <i>Journal of Neurology</i> , <b>2014</b> , 261, 773-83	5.5	136
107	Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. <i>Journal of Neurology</i> , <b>2014</b> , 261, 316-23	5.5	15
106	Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. <i>Current Medical Research and Opinion</i> , <b>2014</b> , 30, 613-27	2.5	53
105	Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 253-7	5	36
104	Lymphocyte subset dynamics following alemtuzumab treatment in patients who relapsed on a prior therapy. <i>Journal of Neuroimmunology</i> , <b>2014</b> , 275, 63-64	3.5	1

103	Complement activation in patients with neuromyelitis optica. <i>Journal of Neuroimmunology</i> , <b>2014</b> , 274, 185-91	3.5	40
102	Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2014</b> , 143, 424-33	5.1	13
101	Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2014</b> , 85, 859-64	5.5	27
100	Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. <i>Journal of Neurology</i> , <b>2014</b> , 261, 1735-44	5.5	38
99	Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. <i>Neurology</i> , <b>2014</b> , 83, 1210-6	6.5	26
98	Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel. <i>Multiple Sclerosis and Related Disorders</i> , <b>2014</b> , 3, 513-9	4	32
97	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. <i>Lancet Neurology</i> , <b>2014</b> , 13, 472-81	24.1	77
96	Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 464-70	5	23
95	MRI correlates of disability progression in patients with CIS over 48 months. <i>NeuroImage: Clinical</i> , <b>2014</b> , 6, 312-9	5.3	32
94	Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment. <i>Journal of the Neurological Sciences</i> , <b>2014</b> , 347, 229-34	3.2	8
93	Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. <i>Neurology</i> , <b>2014</b> , 82, 573-81	6.5	200
92	The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis. <i>JAMA Neurology</i> , <b>2014</b> , 71, 1386-93	17.2	38
91	Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: results from the multi-center set study. <i>Journal of Neuroimmunology</i> , <b>2014</b> , 273, 58-64	3.5	16
90	Future MS care: a consensus statement of the MS in the 21st Century Steering Group. <i>Journal of Neurology</i> , <b>2013</b> , 260, 462-9	5.5	22
89	Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. <i>JAMA Neurology</i> , <b>2013</b> , 70, 248-51	17.2	11
88	Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS). <i>CNS Neuroscience and Therapeutics</i> , <b>2013</b> , 19, 302-6	6.8	9
87	Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. <i>N Engl J Med</i> 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. <i>N Engl J Med</i> 2012;367:1087-97. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 2145-56	4	28
86	Oral BG-12 in multiple sclerosis. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 1652-3	59.2	2

85	Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: results of a 5-year follow-up study. <i>Clinical Neurology and Neurosurgery</i> , <b>2013</b> , 115 Suppl 1, S42-8	2	6
84	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2013</b> , 381, 2167-75	40	236
83	Symptoms and diagnosis of multiple sclerosis <b>2013</b> , 36-48		0
82	Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. <i>Journal of Neuroimmunology</i> , <b>2013</b> , 263, 121-7	3.5	10
81	Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome. <i>Genes and Immunity</i> , <b>2013</b> , 14, 244-8	4.4	14
80	Leukocyte counts in cerebrospinal fluid and blood following finte-grast treatment in subjects with relapsing forms of multiple sclerosis. <i>European Journal of Neurology</i> , <b>2013</b> , 20, 1032-42	6	5
79	Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. <i>Journal of Neurology</i> , <b>2013</b> , 260, 2286-96	5.5	50
78	Thalamic atrophy is associated with development of clinically definite multiple sclerosis. <i>Radiology</i> , <b>2013</b> , 268, 831-41	20.5	119
77	Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years. <i>American Journal of Neuroradiology</i> , <b>2013</b> , 34, 1931-9	4.4	68
76	Lipid profiles are associated with lesion formation over 24 months in interferon- $\beta$ treated patients following the first demyelinating event. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2013</b> , 84, 1186-91	5.5	87
75	Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study. <i>Multiple Sclerosis International</i> , <b>2013</b> , 2013, 231345	1.1	6
74	How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?. <i>Frontiers in Neurology</i> , <b>2013</b> , 4, 10	4.1	17
73	Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study. <i>PLoS ONE</i> , <b>2013</b> , 8, e53996	3.7	50
72	Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. <i>Lancet Neurology, The</i> , <b>2012</b> , 11, 420-8	24.1	128
71	Early predictors of non-response to interferon in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , <b>2012</b> , 126, 390-7	3.8	21
70	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. <i>Lancet, The</i> , <b>2012</b> , 380, 1819-28	40	834
69	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. <i>Lancet, The</i> , <b>2012</b> , 380, 1829-39	40	827
68	Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group. <i>Wiener Medizinische Wochenschrift</i> , <b>2012</b> , 162, 354-66 <sup>2.9</sup>		11

67	Restless legs syndrome in Czech patients with multiple sclerosis: an epidemiological and genetic study. <i>Sleep Medicine</i> , <b>2012</b> , 13, 848-51	4.6	33
66	Cost of multiple sclerosis in the Czech Republic: the COMS study. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 662-8	5	32
65	Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 143-52	5	186
64	Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 1087-97	59.2	943
63	Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 314-21	5	57
62	Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. <i>Clinical Neurology and Neurosurgery</i> , <b>2012</b> , 114, 940-6	2	16
61	Cross cultural validation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). <i>Clinical Neuropsychologist</i> , <b>2012</b> , 26, 1186-200	4.4	88
60	Corpus callosum atrophy--a simple predictor of multiple sclerosis progression: a longitudinal 9-year study. <i>European Neurology</i> , <b>2012</b> , 68, 23-7	2.1	26
59	Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study. <i>PLoS ONE</i> , <b>2012</b> , 7, e50101	3.7	62
58	Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. <i>Journal of Neurology</i> , <b>2012</b> , 259, 898-905	5.5	54
57	Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: yes. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 1209-10	5	2
56	Subcortical and cortical gray matter atrophy in a large sample of patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. <i>American Journal of Neuroradiology</i> , <b>2012</b> , 33, 1573-8	4.4	112
55	Interferon- $\beta$ or azathioprine as add-on therapies in patients with active multiple sclerosis. <i>Neurological Research</i> , <b>2012</b> , 34, 923-30	2.7	7
54	Clinical Efficacy of BG-12 in Relapsing-Remitting Multiple Sclerosis (RRMS): Data from the Phase 3 CONFIRM Study (S01.003). <i>Neurology</i> , <b>2012</b> , 78, S01.003-S01.003	6.5	4
53	Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome. <i>PLoS ONE</i> , <b>2012</b> , 7, e38661	3.7	29
52	HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. <i>Journal of Neuroimmunology</i> , <b>2011</b> , 236, 76-80	3.5	10
51	Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. <i>Lancet Neurology</i> , <b>2011</b> , 10, 745-58	24.1	212
50	BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. <i>Journal of Neurology</i> , <b>2011</b> , 258, 449-56	5.5	41



49	Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. <i>Annals of Neurology</i> , <b>2011</b> , 69, 292-302	9.4	6480
48	Freedom from disease activity in multiple sclerosis. <i>Neurology</i> , <b>2010</b> , 74 Suppl 3, S3-7	6.5	105
47	Risks of immune system treatments. <i>Science</i> , <b>2010</b> , 328, 825-6	33.3	20
46	High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. <i>Multiple Sclerosis Journal</i> , <b>2010</b> , 16, 685-93	5	64
45	Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. <i>Multiple Sclerosis Journal</i> , <b>2010</b> , 16, 1360-6	5	52
44	Patients stratification and correlation of brain magnetic resonance imaging parameters with disability progression in multiple sclerosis. <i>European Neurology</i> , <b>2009</b> , 61, 278-84	2.1	8
43	Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2009</b> , 15, 965-76	5	67
42	Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. <i>Lancet Neurology</i> , <b>2009</b> , 8, 254-60	24.1	348
41	Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. <i>Lancet Neurology</i> , <b>2009</b> , 8, 1111-9	24.1	192
40	The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. <i>Journal of Neurology</i> , <b>2009</b> , 256, 405-15	5.5	164
39	Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study. <i>Journal of the Neurological Sciences</i> , <b>2009</b> , 282, 112-9	3.2	69
38	Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. <i>Lancet</i> , <b>2008</b> , 371, 2085-92	40	236
37	Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. <i>Lancet</i> , <b>2008</b> , 372, 1463-72	49	398
36	Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2008</b> , 79, 407-14	5.5	64
35	Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. <i>Journal of Neurology</i> , <b>2008</b> , 255, 1449-63	5.5	173
34	Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. <i>Annals of Neurology</i> , <b>2008</b> , 63, 611-20	9.4	143
33	Neurobiological aspects of depressive disorder and antidepressant treatment: role of glia. <i>Physiological Research</i> , <b>2008</b> , 57, 151-164	2.1	27
32	Regulation of heme degradation in association with multiple sclerosis. <i>FASEB Journal</i> , <b>2008</b> , 22, 1013.3	0.9	

31	Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. <i>Current Medical Research and Opinion</i> , <b>2007</b> , 23, 2823-32	2.5	7
30	Health-related quality of life in multiple sclerosis: effects of natalizumab. <i>Annals of Neurology</i> , <b>2007</b> , 62, 335-46	9.4	136
29	Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. <i>Lancet Neurology</i> , <b>2007</b> , 6, 431-41	24.1	161
28	Natalizumab in the treatment of patients with multiple sclerosis: first experience. <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1110, 465-73	6.5	5
27	Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. <i>Journal of Neurology</i> , <b>2007</b> , 254, 827-37	5.5	45
26	Detection of cortical lesions is dependent on choice of slice thickness in patients with multiple sclerosis. <i>International Review of Neurobiology</i> , <b>2007</b> , 79, 475-89	4.4	22
25	The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. <i>Neurology</i> , <b>2007</b> , 69, 1391-403	6.5	263
24	Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. <i>Neurology</i> , <b>2007</b> , 68, 1299-304	30.4	107
23	MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. <i>Neurology</i> , <b>2007</b> , 68, 1390-401	16.5	260
22	Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. <i>Multiple Sclerosis Journal</i> , <b>2006</b> , 12, 814-23	5	173
21	Azathioprine myelosuppression in multiple sclerosis: characterizing thiopurine methyltransferase polymorphisms. <i>Multiple Sclerosis Journal</i> , <b>2006</b> , 12, 108-11	5	4
20	Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. <i>Archives of Neurology</i> , <b>2006</b> , 63, 614-9		73
19	Comparison of the influence of different rehabilitation programmes on clinical, spirometric and spiroergometric parameters in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2006</b> , 12, 227-34	5.4	67
18	Infusion-related hypersensitivity reactions during natalizumab treatment. <i>Neurology</i> , <b>2006</b> , 67, 1717-8	6.5	39
17	A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 899-910	59.2	2432
16	A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. <i>European Journal of Neurology</i> , <b>2006</b> , 13, 61-71	6	41
15	Aggressive multiple sclerosis-is there a role for stem cell transplantation?. <i>Journal of Neurology</i> , <b>2005</b> , 252 Suppl 3, iii34-iii37	5.5	7
14	Is it possible to actively and purposely make use of plasticity and adaptability in the neurorehabilitation treatment of multiple sclerosis patients? A pilot project. <i>Clinical Rehabilitation</i> , <b>2005</b> , 19, 170-81	3.3	26

13	Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. <i>Archives of Neurology</i> , <b>2005</b> , 62, 1519-30		22
12	Spiroergometric and spirometric parameters in patients with multiple sclerosis: are there any links between these parameters and fatigue, depression, neurological impairment, disability, handicap and quality of life in multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , <b>2005</b> , 11, 213-21	5	24
11	Immunoablative Therapy with Autologous Stem Cell Transplantation in the Treatment of Poor Risk Multiple Sclerosis.. <i>Blood</i> , <b>2005</b> , 106, 5519-5519	2.2	
10	Treatment optimization in multiple sclerosis: report of an international consensus meeting. <i>European Journal of Neurology</i> , <b>2004</b> , 11, 43-7	6	23
9	Markers of bone remodeling predict rate of bone loss in multiple sclerosis patients treated with low dose glucocorticoids. <i>Clinica Chimica Acta</i> , <b>2004</b> , 348, 147-54	6.2	22
8	Myelin basic protein in multiple sclerosis and other neurological disorders. <i>Journal of Neurology</i> , <b>2003</b> , 250, 874-5	5.5	
7	Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. <i>Journal of Neurology</i> , <b>2002</b> , 249, 1088-97	5.5	181
6	Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis. <i>Transplantation Proceedings</i> , <b>2001</b> , 33, 2179-81	1.1	26
5	High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. <i>Bone Marrow Transplantation</i> , <b>2000</b> , 25, 525-31	4.4	74
4	Atrophy of caudate nucleus in Huntington's disease measured by computed tomography. <i>Journal of Neurology</i> , <b>2000</b> , 247, 880-1	5.5	2
3	Occurrence of IgA and IgG autoantibodies to calreticulin in coeliac disease and various autoimmune diseases. <i>Journal of Autoimmunity</i> , <b>2000</b> , 15, 441-9	15.5	41
2	Early clinical markers of aggressive multiple sclerosis		1
1	Immunotherapy prevents long-term disability in relapsing multiple sclerosis over 15 years		1